pharmacological study for Hodgkin Disease
Phase-Based Progress Estimates
Effectiveness
Safety
Hodgkin Disease+2 More
pharmacological study - OtherEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is looking at the side effects and best dose of a cancer treatment that uses a radiolabeled monoclonal antibody, which attaches to cancer cells and delivers a cancer-killing substance, in conjunction with chemotherapy drugs. The trial is for patients whose Hodgkin lymphoma hasn't responded to treatment or has returned after treatment.
Eligible Conditions
- Hodgkin Disease
- Recurrent Adult Hodgkin's Lymphoma
Treatment Effectiveness
Effectiveness Progress
Other trials for Hodgkin Disease
Study Objectives
2 Primary · 8 Secondary · Reporting Duration: Up to 5 years
For 30 days post-transplant
DLT
Year 5
Cumulative incidence of non-relapsed mortality (NRM)
Day 6
Biodistribution of basiliximab
Year 5
Overall survival (OS)
Year 5
Progression free survival (PFS)
Year 5
Response duration
Day 100
Incidence of toxicity
Up to 18 months
RP2D of Yttrium-90 labeled basiliximab
Up to 5 years
Best ORR
Cumulative incidence of relapse/progression incidence
Trial Safety
Safety Progress
Other trials for Hodgkin Disease
Trial Design
1 Treatment Group
Treatment (radiolabeled monoclonal antibody, chemotherapy)
1 of 1
Experimental Treatment
25 Total Participants · 1 Treatment Group
Primary Treatment: pharmacological study · No Placebo Group · Phase 1
Treatment (radiolabeled monoclonal antibody, chemotherapy)Experimental Group · 9 Interventions: laboratory biomarker analysis, carmustine, cytarabine, autologous hematopoietic stem cell transplantation, etoposide, pharmacological study, melphalan, basiliximab, yttrium Y 90-labeled basiliximab · Intervention Types: Other, Drug, Drug, Procedure, Drug, Other, Drug, Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carmustine
FDA approved
Cytarabine
FDA approved
autologous hematopoietic stem cell transplantation
2004
Completed Phase 3
~1630
Etoposide
FDA approved
Melphalan
FDA approved
Basiliximab
FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
12,990 Previous Clinical Trials
41,298,863 Total Patients Enrolled
198 Trials studying Hodgkin Disease
22,973 Patients Enrolled for Hodgkin Disease
City of Hope Medical CenterLead Sponsor
505 Previous Clinical Trials
2,249,002 Total Patients Enrolled
19 Trials studying Hodgkin Disease
1,191 Patients Enrolled for Hodgkin Disease
Eileen SmithPrincipal InvestigatorCity of Hope Medical Center
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
References
- Herrera, Alex F., Joycelynne Palmer, Vikram Adhikarla, Dave Yamauchi, Erasmus K. Poku, James Bading, Paul Yazaki, et al.. 2021. “Anti-cd25 Radioimmunotherapy with BEAM Autologous Hematopoietic Cell Transplantation Conditioning in Hodgkin Lymphoma”. Blood Advances. American Society of Hematology. doi:10.1182/bloodadvances.2021004981.
- Herrera, Alex F., Joycelynne Palmer, Vikram Adhikarla, Dave Yamauchi, Erasmus K. Poku, James Bading, Paul Yazaki, et al.. 2021. “Anti-cd25 Radioimmunotherapy with BEAM Autologous Hematopoietic Cell Transplantation Conditioning in Hodgkin Lymphoma”. Blood Advances. American Society of Hematology. doi:10.1182/bloodadvances.2021004981.
- 2012. "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01476839.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments